Biodirection Inc. has won Breakthrough Device Designation from the U.S. FDA for its Tbit system for the prediction of positive computerized tomography (CT) scans following traumatic brain injury (TBI). The Boston, Mass.-based company expects to shepherd an emergency room-oriented diagnostic through the 510(k) de novo process and onto the market potentially by the end of the first quarter of 2020.